Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,862 across all filing types
Latest filing 2020-06-08 Regulatory Filings
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
6-K Filing
Regulatory Filings
2020-06-08 English
FILGOTINIB DEMONSTRATES DURABLE EFFICACY AND CONSISTENT SAFETY PROFILE AT 52 WEEKS IN FINCH 1 AND 3 STUDIES IN RHEUMATOID ARTHRITIS
Earnings Release Classification · 95% confidence The document is a press release dated June 4, 2020, announcing 52-week results from clinical trials (FINCH 1 and FINCH 3) for the drug filgotinib, presented at the EULAR congress. It details efficacy and safety data, compares results against placebo, adalimumab, and methotrexate, and includes forward-looking statements and company boilerplate. This format—a formal announcement of key periodic results (clinical trial data) outside of a mandatory periodic financial filing (like 10-K or IR)—is characteristic of an Earnings Release (ER) or a general announcement. Since it focuses heavily on clinical trial results and scientific data presentation rather than just quarterly financial highlights, it aligns best with an announcement of scientific/clinical findings, which often accompanies or precedes a formal Earnings Release. However, given the structure (press release format, date, company names, focus on study results), it functions as the initial public disclosure of significant operational/clinical progress. In the context of the provided definitions, this is a high-level announcement of results, making 'Earnings Release' (ER) the most appropriate fit for a major operational/clinical update disseminated via press release, even if the content is scientific rather than purely financial metrics. It is not a full report (10-K, IR), a transcript (CT), or a presentation (IP), but the initial release of the findings. Q1 2020
2020-06-04 English
FILGOTINIB DEMONSTRATES DURABLE EFFICACY AND CONSISTENT SAFETY PROFILE AT 52 WEEKS IN FINCH 1 AND 3 STUDIES IN RHEUMATOID ARTHRITIS
Earnings Release Classification · 95% confidence The document is a press release dated June 4, 2020, announcing Week 52 results from Phase 3 clinical studies (FINCH 1 and FINCH 3) for the drug filgotinib in rheumatoid arthritis. It details efficacy endpoints (ACR20, DAS28, remission rates) and safety profiles, referencing data presented at a medical congress (EULAR). This content structure—announcing clinical trial results and safety data outside of a formal regulatory filing like a 10-K or 10-Q—is characteristic of an Earnings Release (ER) or a general announcement related to financial/operational performance highlights. Since it focuses specifically on the release of key clinical trial data and results, it aligns best with the 'Earnings Release' (ER) category, which often includes operational updates that drive financial performance, or potentially an 'Interim Report' (IR) if it were a comprehensive quarterly filing, but the format strongly suggests a press release highlighting key findings. Given the options, 'ER' (Earnings Release) is the most appropriate fit for a press release summarizing significant clinical trial milestones and safety data, as these announcements often accompany or precede formal earnings reports. It is not a full report (10-K, IR), a transcript (CT), or a presentation (IP). Q2 2020
2020-06-04 English
6-K Filing
Regulatory Filings
2020-06-04 English
Galapagos increases share capital through subscription right exercises
Share Issue/Capital Change Classification · 98% confidence The document is a press release from Galapagos NV announcing a capital increase resulting from the exercise of subscription rights ('kapitaalverhoging door uitoefening van inschrijvingsrechten'). It details the number of new shares issued, the total capital raised (€17.9 million), and updates the total number of voting rights and shares outstanding, referencing Belgian transparency legislation. This content directly relates to changes in the company's capital structure and financing activities. This aligns perfectly with the definition for 'Capital/Financing Update' (CAP). It is not an earnings release (ER), an annual report (10-K), or a general regulatory filing (RNS), as it concerns a specific corporate finance action.
2020-05-29 Dutch
Galapagos increases share capital through subscription right exercises
Share Issue/Capital Change Classification · 99% confidence The document explicitly announces an increase in share capital due to the exercise of subscription rights, detailing the number of new shares issued and the total capital increase amount. This directly relates to changes in the company's capital structure and share count. This aligns perfectly with the definition for 'Share Issue/Capital Change' (SHA). The document is not a general earnings release (ER), an annual report (10-K), or a simple announcement of a report (RPA), but rather the primary disclosure of the capital event itself.
2020-05-29 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.